WKYMVm is a synthetic peptide agonist of formyl peptide receptor 1 (FPR1) and FPR2, which was previously known as formyl peptide receptor-like 1 (FPRL1).1,2,3 It induces calcium mobilization in ETFR rat basophilic leukemia cells transfected with FPR1 or FPR2 when used at a concentration of 0.1 nM.1 WKYMVm stimulates chemotaxis of monocytes, dendritic cells, and natural killer (NK) cells, as well as induces superoxide production in monocytes and neutrophils, in vitro.3 In vivo, WKYMVm (8 mg/kg) reverses mucosal destruction, decreases in body weight, and colonic shortening in a mouse model of colitis induced by dextran sulfate (sodium salt) . Topical application of WKYMVm stimulates angiogenesis and accelerates re-epithelialization and granulation tissue formation in a rat model of diabetic cutaneous wounds.2
1.Le, Y., Gong, W., Li, B., et al.Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activationJ. Immunol.163(12)6777-6784(1999) 2.Kwon, Y.W., Heo, S.C., Jang, I.H., et al.Stimulation of cutaneous wound healing by an FPR2-specific peptide agonist WKYMVmWound Repair Regen.23(4)575-582(2015) 3.Kim, S.D., Kwon, S., Lee, S.K., et al.The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitisExp. Mol. Med.45(9)e40(2013)